A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors
Status:
Not yet recruiting
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of the study drug KN046 in patients with
advanced thymic carcinoma who progressed after prior treatment with immune checkpoint
inhibitor therapy.